IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection

Current Opinion in Molecular Therapeutics

Volumn 10, Issue 4, 2008, Pages 407-417

  Jones, T ^a  

^a MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; SMALLPOX VACCINE;

ARTHRALGIA; ATOPIC DERMATITIS; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; FEVER; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOT FLUSH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOCOMPROMISED PATIENT; IMMUNOREACTIVITY; INJECTION SITE INDURATION; INJECTION SITE PAIN; LYMPHADENOPATHY; MALAISE; MUSCULOSKELETAL PAIN; NAUSEA; NONHUMAN; REVIEW; SIDE EFFECT; SMALLPOX; UNSPECIFIED SIDE EFFECT; VACCINIA ANKARA VIRUS; VACCINIA VIRUS;

ANIMALS; CLINICAL TRIALS AS TOPIC; DERMATITIS, ATOPIC; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, ANCIENT; HIV INFECTIONS; HUMANS; SMALLPOX; SMALLPOX VACCINE; VACCINES, ATTENUATED; VACCINIA VIRUS;

VARIOLA VIRUS;

EID: 49249097527     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. 319289 Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: Propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Carroll M, Moss B VIROLOGY 1997 238 2 198-211
2. 451097 Bavarian Nordic A/S - first quarterly statement 2002 Bavarian Nordic Research Institute A/S PRESS RELEASE 2002 May 14
3. 479876 Bavarian Nordic gets smallpox vaccine contract in US. Bavarian Nordic Research Institute A/S Pres Release 2003 February 26
4. 480070 Bavarian Nordic starts MVA-BN phase II program. Bavarian Nordic Research Institute A/S PRESS RELEASE 2003 February 26
5. 515821 VaxGen and Kaketsuken announce agreement to make potentially safer smallpox vaccine for US. VaxGen Inc PRESS RELEASE 2002 December 17
6. 531894 ACAM2000 clinical trials update. Acambis plc PRESS RELEASE 2004 April 13
7. 537979 Bavarian Nordic's smallpox vaccine shows promise in phase II study. Bavarian Nordic A/S PRESS RELEASE 2004 May 11
8. 550125 Imvamune smallpox vaccine gets Fast Track status Bavarian Nordic A/S PRESS RELEASE 2004 July 21
9. 557473 Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: Implications for use as a human vaccine. Blanchard TJ, Alcami A, Andrea P, Smith GL J GEN VIROL 1998 79 5 1159-1167
10. 561734 Bavarian Nordic awarded smallpox vaccine contract by US government. Bavarian Nordic A/S Pres Release 2004 September 30
11. 565521 VaxGen begins clinical development of its attenuated smallpox vaccine candidate. VaxGen Inc Pres Release 2004 October 20
12. 568930 A phase II dose finding trial with 165 vaccinia naive subjects to assess safety and immunogenicity of a third generation smallpox vaccine. Krempelhuber A, Vollmar J, Pokorny R, Seiberling M, Nauer T, Rapp P, Petzold B, Handley A, Wulff N, Chaplin P ICAAC 2004 44 Washington Abs G-557
13. 606527 Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. Stittelaar K, van Amerongen G, Kondova I, Kuiken T, van Lavieren R, Pistoor F, Niesters H, van Doornum G, van der Zeijst B, Mateo L J Virol 2005 79 12 7845-7851
14. 613365 Bavarian Nordic starts phase II trial of smallpox vaccine in HIV patients Bavarian Nordic A/S PRESS RELEASE 2005 July 20
15. 618963 Interim results as of 30 June 2005 and update on company developments. Bavarian Nordic A/S PRESS RELEASE 2005 August 22
16. 620256 ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) - A second generation smallpox vaccine for biological defense. Monath TP, Caldwell JR, Mundt W, Fusco J, Johnson CS, Buller M, Liu J, Gardner B, Downing G, Blum PS, Kemp T et al Int J Infect Dis 2004 8 Suppl 2 S31-S44
17. 620259 A novel cell culture derived smallpox vaccine in vaccinia naive adults. Artenstein AW, Johnson C, Marbury TC, Morrison D, Blum PS, Kemp T, Nichols R, Balser JP, Currie M, Monath TP Vacine 2005 23 25 3301-3309
18. 620811 Bavarian Nordic A/S enforces its intellectual property rights against Acambis plc and Acambis Inc. Bavarian Nordic A/S Pres Release 2005 August 19
19. 642587 Bavarian Nordic business update. Bavarian Nordic A/S PRESS RELEASE 2005 December 22
20. 657400 Bavarian Nordic A/S - Annual results 2005. Bavarian Nordic A/S PRESS RELEASE 2006 March 22
21. 668565 Acambis plc - Opposition to MVA patent. Acambis plc Pres Release 2006 May 19
22. 680917 Acambis's smallpox vaccine is safe and immunogenic in phase II trial. Acambis plc PRESS RELEASE 2006 July 31
23. 683858 Bavarian Nordic A/S - Interim report for the period 1 January to 30 June 2006. Bavarian Nordic A/S PRESS RELEASE 2006 August 11
24. 728344 Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vollmar J, Arndtz N, Eckl KM, Thomsen T, Petzold B, Mateo L, Schlereth B, Handley A, King L, Hulsemann TMV et al Vacine 2006 24 12 2065-2070
25. 753221 Bavarian's IMVAMUNE effective as smallpox vaccine in HIV patients. Bavarian Nordic A/S PRESS RELEASE 2006 December 21
26. 755191 BN ImmunoTherapeutics starts trials with new breast cancer vaccine. Bavarian Nordic A/S Pres Release 2007 January 04
27. 775386 Results for the year ended 31 December 2006 and business update. Acambis plc Pres Release 2007 March 15
28. 787695 Bavarian Nordic A/S - Interim Report as of 31 March 2007. Bavarian Nordic A/S Pres Release 2007 April 26
29. 801701 Bavarian Nordic awarded $500 million US HHS contract for MVA-BN smallpox vaccine. US Department of Health and Human Services Pres Release 2007 June 05
30. 802192 Smallpox vaccination and its consequences: First experiences with the highly attenuated smallpox vaccine 'MVA'. Stickl HA Prev Med 1974 3 1 97-101
31. 803555 VaxGen and Kaketsuken end smallpox vaccine partnership. VaxGen Inc Pres Release 2007 June 11
32. 816113 Acambis and Bavarian end MVA patent dispute. Bavarian Nordic A/S Pres Release 2007 July 26
33. 836304 US government extends MVA-BN contract with Bavarian to include atopic dermatitis. Bavarian Nordic A/S Pres Release 2007 October 04
34. 848410 BN discontinues MVA-BN HIV nef to focus on multiantigen HIV infection program. Bavarian Nordic A/S Pres Release 2007 November 06
35. 856020 Bavarian Nordic reports positive data from first EUA enabling study with IMVAMUNE smallpox vaccine candidate. Bavarian Nordic A/S PRESS RELEASE 2007 November 29
36. 862886 Bavarian Nordic receives $25 million milestone payment from HHS for fulfilling contract milestones. Bavarian Nordic A/S Pres Release 2007 December 20
37. 873131 Clinical and immunologic responses to multiple doses of IMVAMUNE (modified vaccinia Ankara) followed by DryVax challenge. Frey SE, Newman FK, Kennedy JS, Sobek V, Ennis FA, Hill H, Yan LK, Chaplin P, Vollmar J, Chaitman BR, Belshe RB Vacine 2007 25 51 8562-8573
38. 876749 Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus Ankara is comparable to that of Dryvax. Davies DH, Wyatt LS, Newman FK, Earl PL, Chun S, Hernandez JE, Molina DM, Hirst S, Moss B, Frey SE, Felgner PL J VIROL 2008 82 2 652-663
39. 891644 Bavarian Nordic A/S - Annual results 2007. PRESS RELEASE 2008 March 31
40. 895271 Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. Samuelsson C, Hausmann J, Lauterbach H, Schmidt M, Akira S, Wagner H, Chaplin P, Suter M, O'Keeffe M, Hochrein H J Clin Invest 2008 118 5 1776-1786
41. 896902 SIGA submits ST-246 for EU approval for smallpox. SIGA Technologies Inc PRESS RELEASE 2008 April 15
42. 897572 Smallpox: The triumph over the most terrible of the ministers of death. Barquet N, Domingo P Ann Intern Med 1997 127 8 Pt 1 635-642 • This study provided an excellent background to smallpox, its history and the history of smallpox vaccination.
43. 897573 Dendritic cells from mice neonatally vaccinated with modified vaccinia virus Ankara transfer resistance against herpes simplex virus type I to naive one-week-old mice. Franchini M, Hefti H, Vollstedt S, Glanzmann B, Riesen M, Ackermann M, Chaplin P, Shortman K, Suter M J IMMUNOL 2004 172 10 6304-6312
44. 897577 Adverse events associated with smallpox vaccination in the United States, January-October 2003. Casey CG, Iskander JK, Roper MH, Mast EE, Wen XJ, Torok TJ, Chapman LE, Swerdlow DL, Morgan J, Heffelfinger JD, Vitek C et al J AM MED ASSOC 2005 294 21 2734-2743 • This study provided a detailed description of the adverse events associated with the use of the first-generation smallpox vaccine and highlights the problems faced in developing new-generation smallpox vaccines.
45. 897581 An update on smallpox vaccine candidates and their role in bioterrorism related vaccination strategies. Wiser I, Balicer RD, Cohen D Vacine 2007 25 6 976-984
46. 905722 Bavarian Nordic A/S - Annual report 2007. Bavarian Nordic A/S ANNUAL REPORT 2008 March 31
47. 906947 Smallpox. Moore ZS, Seward JF, Lane JM Lancet 2006 367 9508 425-435 • This study provided an excellent background to the smallpox disease.
48. 910329 Bavarian Nordic starts phase I/II trial of anti-HIV vaccine. Bavarian Nordic A/S Pres Release 2008 May 27
49. 913141 BN ImmunoTherapeutics starts clinical trials with prostate cancer vaccine. BN Immunotherapeutics Inc Pres Release 2008 June 04
50. 913156 WHO fact sheet: Smallpox. WHO Web site 2008 June 04
51. 913173 Top 10 infectious diseases that have killed millions of people. Anitei A Web site 2007 November 13
52. 913179 7 Worst killer plagues in history. Oddee Web site 2007 October 15
53. 913245 Government report says 3 nations hide stocks of smallpox. The New York Times Web site 1999 June 13
54. 913256 NIH's role in implementing a smallpox vaccination program. Fauci AS US DEPARTMENT HEALTH HUM SERVICES 2003 January 29
55. 913259 The US smallpox vaccination program: A review of a large modern era smallpox vaccination implementation program. Poland GA, Grabenstein JD, Neff JM Vacine 2005 23 17-18 2078-2081
56. 913295 Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA. Mayr A, Hochstein-Mintzel V, Stickl H Infection 1975 3 6-14
57. 914730 NCT00565929: Safety, reactogenicity and immunogenicity of MVA in HSCT subjects. National Institute of Allergy and Infectious Diseases clinicaltrials.gov 2008 June 05
58. 914790 Randomized, controlled, phase II study with an MVA-nef vaccine in HIV-1-infected patients with CD4 counts > 250/μl followed by structured treatment interruption. Harrer T, Hain J, Vollmar J, Baedeker N, Sobek V, Jaeger H, Helm M, Gorriahn D, Schneider L, Harrer E INT CONF RETROVIRUSES OPPORTUNISTIC INFECT 2008 January 27
59. 914797 NCT00316589: Safety and immunogenicity of IMVAMUNE (MVA-BN) smallpox vaccine in HIV infected patients. Bavarian Nordic A/S clinicaltrials.gov 2008 June 09
60. 914807 NCT00316602: A phase II study on immunogenicity and safety of MVA-BN (IMVAMUNE) smallpox vaccine in subjects with atopic dermatitis. Bavarian Nordic A/S clinicaltrials.gov 2008 June 09
61. 914813 NCT00437021: MVA post-event: Administration timing and boost study. National Institute of Allergy and Infectious Diseases clinicaltrials.gov 2008 June 09
62. 914816 NCT00686582: An open-label phase II study to evaluate immunogenicity and safety of a single IMVAMUNE booster vaccination two years after the last IMVAMUNE vaccination in former POX-MVA-005 vaccinees. Bavarian Nordic A/S clinicaltrials.gov 2008 May 29
63. 914823 IMVAMUNE: Production. Bavarian Nordic A/S Company World Wide Web site 2008 June 09
64. 914824 Products: MVA-BN. Bavarian Nordic A/S Company World Wide Web site 2008 June 09
65. 915072 The smallpox vaccination strain MVA: Marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. Mayr A, Stickl H, Muller HK, Danner K, Singer H ZENTRALBL BAKTERIOL 1978 167 5-6 375-390
66. 915073 MVA vaccination against smallpox: Clinical tests with an attenuated live vaccinia virus strain (MVA). Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schäfer H, Holzner A DTSCH MED WOCHENSCHR 1974 99 47 2386-2392
67. 915075 Vaccination against pox diseases under immunosuppressive conditions. Mayr A, Danner K DEV BIOL STAND 1978 41 225-234
68. 915077 Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. Meyer H, Sutter G, Mayr A J GEN VIROL 1991 72 5 1031-1038
69. 915672 WO-00242480: Modified vaccinia Ankara virus variant. Bavarian Nordic A/S World Patent 2002 May 30
70. 917008 Acambis: Pipeline. Acambis plc COMPANY WORLD WIDE WEB SITE 2008 June 16
71. 917374 Vaccines for preventing smallpox. Metzger W, Mordmueller BG COCHRANE DATABASE SYST REV 2007 3 CD004913
72. 920210 Bavarian Nordic A/S: Webcast presentation and conference call. Bavarian Nordic A/S COMPANY PRESENTATION 2008 March 31
73. 920382 NCT00390078: Single-blind, controlled safety and immunogenicity study of recombinant MVA virus to treat HIV infection. Bavarian Nordic A/S CLINICALTRIALS.GOV 2008 June 26